- Home
- KRON vs PRLD Comparison
KRON vs PRLD Comparison
Compare KRON & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- PRLD
- Stock Information
- Founded
- KRON 2017
- PRLD 2016
- Country
- KRON United States
- PRLD United States
- Employees
- KRON 8
- PRLD N/A
- Industry
- KRON Medicinal Chemicals and Botanical Products
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- KRON Health Care
- PRLD Health Care
- Exchange
- KRON Nasdaq
- PRLD Nasdaq
- Market Cap
- KRON 54.1M
- PRLD 48.6M
- IPO Year
- KRON 2020
- PRLD 2020
- Fundamental
- Price
- KRON $0.88
- PRLD $0.80
- Analyst Decision
- KRON Buy
- PRLD Strong Buy
- Analyst Count
- KRON 3
- PRLD 2
- Target Price
- KRON $1.63
- PRLD $4.50
- AVG Volume (30 Days)
- KRON 1.4M
- PRLD 230.1K
- Earning Date
- KRON 08-07-2025
- PRLD 08-11-2025
- Dividend Yield
- KRON N/A
- PRLD N/A
- EPS Growth
- KRON N/A
- PRLD N/A
- EPS
- KRON N/A
- PRLD N/A
- Revenue
- KRON $9,192,000.00
- PRLD $7,000,000.00
- Revenue This Year
- KRON N/A
- PRLD N/A
- Revenue Next Year
- KRON N/A
- PRLD N/A
- P/E Ratio
- KRON N/A
- PRLD N/A
- Revenue Growth
- KRON 21.16
- PRLD N/A
- 52 Week Low
- KRON $0.65
- PRLD $0.61
- 52 Week High
- KRON $1.60
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- KRON 65.76
- PRLD 40.96
- Support Level
- KRON $0.87
- PRLD $0.77
- Resistance Level
- KRON $0.90
- PRLD $0.84
- Average True Range (ATR)
- KRON 0.01
- PRLD 0.07
- MACD
- KRON -0.00
- PRLD -0.02
- Stochastic Oscillator
- KRON 40.19
- PRLD 9.35
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.